Article
Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations.
The Journal of biological chemistry - 1 Jul 2025
Watson Sean M, Harvey Edward P, Pishesha Novalia, Ploegh Hidde L, Springer Timothy A
Abstract excerpt
Oncogenic mutations in the epidermal growth factor receptor (EGFR) promote tumorigenesis by stabilizing active or pre-active receptor conformations. Most EGFR-driven cancers are characterized by kinase domain mutations that directly activate the receptor. However, brain cancers such as glioblastoma multiforme (GBM) uniquely harbor mutations in the EGFR ectodomain that allosterically activate the kinase domain....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.